ZIOPHARM Oncology Inc at Raymond James Human Health Innovation Conference (Virtual) Transcript
Okay. I think we'll get started here. Welcome, everyone, to the Raymond James annual healthcare conference. I'm David Novak, senior biotech analyst here at RJ. And today, I have the pleasure of introducing ZIOPHARM, a clinical-stage biotech company utilizing non-viral gene transfer and conditionally activated cytokines to develop novel CAR-T and TCR therapies.
Joining me from the Company today for our informal fireside chat is Heidi Hagen, Interim CEO; and Dr. Raffaele Baffa, CMO. Thank you both very much for taking the time to chat with us today.
Well, thank you, David.
Thank you.
Questions & Answers
So, Heidi, perhaps a good place to kick us off today would be a bit of a discussion around some of the history of the Company, to the extent that you can speak to it.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |